SBI Holdings Co., Ltd.
SBI Pharma Co., Ltd.
SBI Pharma Co., Ltd. (Headquarters: Minato-ku, Tokyo, Representative Director), a subsidiary of SBI Holdings Co., Ltd., which conducts research and development of pharmaceuticals, health foods and cosmetics using 5-aminolevulinic acid (ALA) (* 1). Executive Officer and President: Yoshitaka Kitao, hereinafter referred to as “SBI Pharma”) published a research paper on the safety and usefulness of ALA for patients with type 2 diabetes in Bahrain on September 23, in the specialized journal “Journal of Diabetes Research”. We are pleased to inform you that we have announced it in.
SBI Pharma and Bahrain Defense Force Hospital / Royal Medical Services are already on the market with the approval of the Bahrain National Health Supervision Agency (NHRA) for ALA and ferrous citrate (SFC) (* 2). A food intervention study with high doses of ALA (up to 200 mg / day) and SFC (up to 229.42 mg / day) was conducted in patients with type 2 diabetes who lived in Bahrain and were on medication with this supplement. ..
Fifty-three subjects were enrolled, of whom 35 took ALA and SFC on prescription drugs and 18 took placebo (a fake diet without ALA and SFC) on prescription drugs for 12 weeks and had blood glucose. In addition to HbA1c (hemoglobin A1c), parameters related to liver function, renal function, iron, etc. were measured.
There were no significant differences between the ALA and SFC-fed group and the placebo group in terms of adverse events identified during the study. In addition, no significant changes were observed in the measured values of liver function, renal function, iron, etc., so it is safe for type 2 diabetic patients on medication to take 200 mg of ALA per day in two divided doses. The sex was confirmed.
HbA1c, which is thought to be closely related to diabetes, gradually decreased during the study period in the group receiving ALA and SFC, and decreased by an average of 0.8% after the 12th week. On the other hand, in the group receiving only the existing type 2 diabetes drug, it decreased until the 6th week, but then started to increase, and after the 12th week, it decreased by only 5%. Furthermore, in the group of patients who received a sulfonylurea agent (* 3) that promotes insulin secretion but the blood glucose level did not decrease, it was observed that the blood glucose level decreased by 0.95% after the 12th week due to the intake of ALA and SFC. It was suggested to overcome tolerance. These results indicate the usefulness of supplemental intake of ALA and SFC for patients with type 2 diabetes who are on medication.
[Announcement]
Specialized journal name: Journal of Diabetes Research
Title: The safety and tolerability of 5-aminolevulinic acid phosphate with sodium ferrous citrate in patients with type 2 diabetes mellitus in Bahrain
Authors: Feryal Al-Saber, Waleed Aldosari, Mariam Alselaiti, Hesham Khalfan, Ahmed Kaladari, Ghulam Khan, George Harb, Riyadh Rehani, Sizuka Kudo, Aya Koda, Tohru Tanaka, Motowo Nakajima, and Abdulla Darwish
Vol. No .: Volume 2016 (2016), Article ID 8294805, 10 pages.
DOI: 10.1155/2016/8294805
Journal Abstract: https://www.hindawi.com/journals/jdr/2016/8294805/abs/
No comment